Geron Corporation
GERNGeron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How GERN's past catalysts played out
Imetelstat
Myelofibrosis
Imetelstat sodium
Locally Recurrent or Metastatic Breast Cancer
Imetelstat 4.7 mg/kg
Myelofibrosis
Imetelstat (7.5 mg/kg)
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Imetelstat | Phase 3 | Myelofibrosis | - | - |
Imetelstat sodium | Phase 3 | Locally Recurrent or Metastatic Breast Cancer | - | - |
Imetelstat 4.7 mg/kg | Phase 2 | Myelofibrosis | - | - |
Imetelstat (7.5 mg/kg) | Phase 2 | Multiple Myeloma | - | - |
Myelofibrosis
2 drugs in this indication
Multiple Myeloma
1 drug in this indication
Locally Recurrent or Metastatic Breast Cancer
1 drug in this indication
Non-small Cell Lung Cancer
1 drug in this indication
Myelodysplastic Syndromes
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Geron Corporation's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Geron Corporation's (GERN) pipeline across Phase 3, Phase 2. Its lead program is Imetelstat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Geron Corporation's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Geron Corporation (GERN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GERN biotech catalysts?→
Add GERN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Geron Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.